Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Cost of Revenue: 2019-2025

Historic Cost of Revenue for Coherus Oncology (CHRS) over the last 6 years, with Sep 2025 value amounting to $3.7 million.

  • Coherus Oncology's Cost of Revenue rose 36.35% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 34.02%. This contributed to the annual value of $117.6 million for FY2024, which is 26.06% down from last year.
  • As of Q3 2025, Coherus Oncology's Cost of Revenue stood at $3.7 million, which was up 9.60% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Cost of Revenue peaked at $111.6 million during Q4 2024, and registered a low of $1.4 million during Q1 2024.
  • Its 3-year average for Cost of Revenue is $26.0 million, with a median of $3.7 million in 2025.
  • Per our database at Business Quant, Coherus Oncology's Cost of Revenue soared by 495.46% in 2023 and then plummeted by 92.72% in 2024.
  • Over the past 5 years, Coherus Oncology's Cost of Revenue (Quarterly) stood at $12.1 million in 2021, then grew by 17.33% to $14.2 million in 2022, then soared by 495.46% to $84.6 million in 2023, then soared by 31.94% to $111.6 million in 2024, then spiked by 36.35% to $3.7 million in 2025.
  • Its Cost of Revenue stands at $3.7 million for Q3 2025, versus $3.4 million for Q2 2025 and $2.7 million for Q1 2025.